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SUMMARY. The present research work describes comprehensive stress testing of eprosartan mesylate
(EM) according to ICH guideline Q1A (R2), and development of a stability-indicating reversed phase ultra
performance liquid chromatographic (UPLC) assay. The drug was subjected to acid (0.5N HCl), neutral
and alkaline (0.5 N NaOH) hydrolytic conditions at 80 °C, and to oxidative decomposition at room temper-
ature. Photolysis was carried out by exposing the drug during the day time to sunlight (60,000–70,000 lux)
for two days and oxidative study was performed with 0.5 mg/ml in 30 % hydrogen peroxide (H2O2) at
room temperature for 25 hr. The solid drug was also subjected to 50 °C for 30 days in a hot air oven.
Degradation of the drug was found to occur under alkaline, acidic and neutral hydrolytic conditions. Sep-
aration of the drug and the degradation products was successfully achieved on a BEH (bridged ethylene
hybrid) C18 column (1.7 μm, 2.1 mm × 150 mm) with gradient elution of water–acetonitrile as mobile
phase. The flow rate and detection wavelength were 0.1 ml/min and 232 nm, respectively. The method was
validated and the response was found to be linear in the drug concentration range 5–25 μg/ml (r2 = 0.999).
The %RSD in intra-day and inter-day precision studies was < 0.8 %. Recovery of the drug from a mixture
of degradation products was between 98.3 and 99.8 %. The LOD and LOQ of developed method were ob-
tained at 0.15 μg/ml and 0.45 μg/ml respectively. The method was specific to the drug, selective to degra-
dation products, and robust. PDA purity test also confirmed the specificity of the method.
